MENU

Members

Matsumura, Yasuhiro

Research contents (Research key words)

Cancer induced blood coagulation, antibody therapeutics, ADC, Cancer stromal targeting (CAST) therapy, Thrombolysis

Biography

Place of Birth: Hitoyoshi City, Kumamoto Prefecture Japan.

• 1975-1981

  MD student, Kumamoto University Medical School

• 1981-1982

  Trainee, First Department of Surgery, Kumamoto University Medical School.

• 1982-1983

  Trainee, Department of Surgery, Saiseikai Kumamoto Hospital

• 1983-1984

  Trainee, Department of Surgery, Kyushyu Memorial Hospital

• 1984-1988

  Postgraduate student, Department of Microbiology, Kumamoto University Medical School

• 1988-1989

  Assistant Professor, Department of Microbiology, Kumamoto University Medical School

• 1989-1990

  Postdoctoral Fellow, Department of Neoplastic Diseases, Mount Sinai Medical Center

• 1990-1993

  Postdoctoral Fellow, Nuffield Department of Pathology, John Radcliffe Hospital, Oxford University

• 1993-1994

  Senior Clinical Research Scientist, Nuffield Department of Pathology John Radcliffe Hospital, Oxford University.

• 1994-1999

  Staff Physician, Department of Medicine, National Cancer Center Hospital.

• 1999-2002

  Head, Department of Medicine, National Cancer Center Hospital.

• 2002-2020

  Director, Division of Dvelopmental Therapeutics, EPOC, National Cancer Center

• 2008-2020

  Director, Translational Research Committee, Japan Clinical Oncology Group

• 2013-2020

  Visiting Professor,  Laboratory of  Cancer Biology, Department of Integrated Biosciences, Graduate School of Frontier Science, The University of Tokyo

• 2014-2020

  Visiting Professor, Department of Medicine, Keio University

• 2018-2020

  Visiting Professor, Kansai Medical School

Awards

• 2005

  Japan  DDS  Nagai Memorial Award.

• 2006

  Tamiya Memorial Award

• 2016

  Thomson Reuters Citation Laureate Chemistry

• 2019

  Kobayashi  Foundation for Cancer Research

Performance

1. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Matsumura Y, Maeda H. Cancer Res. 46, 6387-6392 (1986)
2. Significance of CD44 gene-products for cancer-diagnosis and disease evaluation. Matsumura Y, Tarin D. LANCET 340, 1053-1058 (1992)
3. Phase I and Pharmacokinetic Study of MCC-465, a doxorubicin (DXR) encapsulated in PEG-immunoliposome, in patients with metastatic stomach cancer. Matsumura Y, Gotoh M, Muro K, Yamada Y, Shirao K, Shimada Y, Okuwa M, Matsumoto S, Miyata Y, Ohkura H, Chin K, Baba S, Yamao T, Kannami A, Takamatsu Y, Ito K, Takahashi K  Annals Oncol  15, 517-525 (2004)
4. Cancer-stroma targeting therapy by cytotoxic immunoconjugate bound to the collagen 4 network in the tumor tissue. Yasunaga M, Manabe S, Tarin D, Matsumura Y. Bioconjug Chem. 22, 1776-83 (2011)
5. New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots. Yasunaga M, Manabe S, Matsumura Y. Cancer Sci. 102, 1396-1402 (2011)
6. Cancer stromal targeting (CAST) therapy. Matsumura Y, Adv Drug Deliv Rev 64, 710-719 (2012)
7. Discovery of an uncovered region in fibrin clots and its clinical significance. Hisada Y, Yasunaga M, Hanaoka S, Saijou S. Sugino T, Tsuji A, Saga T, Tsumoto K, Manabe S,. Kuroda J, Kuratsu J, Matsumura Y. Sci. Rep. 3, 2604 (2013)
8. Antitumor effect of anti-tissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts. Koga Y, Manabe S, Aihara Y, Sato R, Tsumura R, Iwafuji H, Furuya F, Fuchigami H, Fujiwara Y, Hisada Y, Yamamoto Y, Yasunaga M, Matsumura Y. Int. J. Cancer 137, 1457-1466 (2015)
9. Tumor imaging by detecting fibrin clots in tumour stroma with anti-fibrin Fab fragment. Obonai T, Fuchigami H, Furuya F, Kozuka N, Yasunaga M, Matsumura Y. Sci. Rep. 6, 23613 (2016)
10. Imaging mass spectrometry for the exquisite design of antibody-drug conjugates. Fujiwara Y, Furuta M, Manabe S, Koga Y, Yasunaga M, Matsumura Y. Sci. Rep. 6, 24954 (2016)
11. Vascular bursts enhance permeability of tumour blood vessels and improve nanoparticle delivery. Matsumoto Y, Nichols JW, Toh K, Nomoto T, Cabral H, Miura Y, Christie RJ, Yamada N, Ogura T, Kano MR, Matsumura Y, Nishiyama N, Yamasoba T, Bae YH, Kataoka K., Nat. Nanotechnol. 11, 533-538 (2016)
12. Molecular imaging using an anti-human tissue factor monoclonal antibody in an orthotopic glioma xenograft model. Takashima H, Tsuji AB, Saga T, Yasunaga M, Koga Y, Kuroda JI, Yano S, Kuratsu JI, Matsumura Y. Sci. Rep. 7, 12341 (2017)
13. Targeting anticoagulant protein S to improve hemostasis in hemophilia. Prince R, Bologna L, Manetti M, Melchiorre D, Rosa I, Dewarrat N, Suardi S, Amini P, Fernandez JA, Burnier L, Quarroz C, Cara MDR, Matsumura Y, Hovinga JAK, Griffin JH, Simon H-U, Ibba-Manneschi L, Saller F, Carzavarini S, Angelillo-Scherrer A.  Blood 131, 1360-1371 (2018)
14. Influence of the dissociation rate constant on the intra-tumor distribution of antibody-drug conjugate against tissue factor. Tsumura R, Manabe S, Takashima H, Koga Y, Yasunaga M, Matsumura Y, J Control Release 284, 49-56 (2018)
15. Chemotherapy payload of anti-insoluble fibrin antibody-drug conjugate is released specifically upon binding to fibrin. Fuchigami H, Manabe S, Yasunaga M, Matsumura Y, Sci Rep 8, 14211-14219 (2018)
16. Topological analysis of TMEM180, a newly identified membrane protein that is highly expressed in colorectal cancer cells. Anzai T & Matsumura Y Biochem Biophys Res Commun 10:520:566-572 (2019)
17. Cancer Drug Delivery Systems based on the Tumor Microenvironment. Matsumura Y and Tarin D (eds.) Springer (2020)
18. Reinforcement of antitumor effect of micelles containing anticancer drugs by binding of an anti-tissue factor antibody without direct cytocidal effects. Takashima H, Koga Y, Tsumura R, Yasunaga M, Tsuchiya M, Inoue T,  Negishi  E, Harada M, Yoshida S, Matsumura Y J Control Release  323: 138-150:2020

Affiliation Society

• President of the board of directors of Japan Society of Drug Delivery System
• A board member of Japanese Cancer Association
• A board member of Japanese Society of Clinical Oncology
• Editorial board of Cancer Science
• Editorial board of  Scientific Reports
• Editorial board of World Journal of Gastroenterology
• Director of Translational Research Committee of Japan Clinical Oncology Group